Dr. Thomas Mehrling reports

HELIX BIOPHARMA CORP. ANNOUNCES CFO APPOINTMENT TO SUPPORT STRATEGIC GROWTH AND UPCOMING MILESTONES

Helix BioPharma Corp. has appointed Rohit Babbar, CPA, as chief financial officer of the company, replacing James B. Murphy, CPA, as fractional CFO.

Mr. Babbar is certified public accountant with 14 years of experience leading accounting operations and financial strategy across fast-growing private and publicly listed small to mid-sized companies in Canada and the United States. He is a director at Brio Financial Group, a financial consulting firm that provides outsourced CFO services, financial planning and analysis, and strategic advisory support to emerging growth companies. Over the course of his career, Mr. Babbar has delivered impact across strategic growth and operational efficiency, leading transformative initiatives, such as a $50-million (U.S.) private equity deal that helped drive a tenfold revenue increase from $20-million (U.S.) to $200-million (U.S.). Mr. Babar will be supported by an experienced team of professionals from Brio, specializing in accounting and finance, capital raising and administrative operations, as Helix enters a new phase of growth that includes plans to relocate to the U.S., pursue a Nasdaq Stock Market listing and close a substantial equity financing to support upcoming clinical studies.

"Rohit's leadership and Brio's support will provide the bandwidth we need as we prepare to execute on the company's upcoming strategic milestones, particularly as we gear up for our interactions with the FDA, ensuring our financial operations are aligned and fully resourced to support clinical execution," said Dr. Thomas Mehrling, MD, PhD, chief executive officer of Helix BioPharma.

Mr. Babbar added: "I'm excited to join Helix at such a pivotal stage in its evolution. The company's scientific foundation and strategic direction present a compelling opportunity to build long-term value. I look forward to working closely with the team to help drive its financial strategy and support its upcoming milestones."

About Brio Financial Group

Brio Financial Group is a financial and management consulting firm based in Somerville, N.J., specializing in outsourced financial leadership and reporting support for small to mid-sized public and private companies. With a team experienced across domestic and international markets, Brio has supported clients listed on multiple stock exchanges and is frequently referred by leading audit firms, including sole practitioners and Big Four firms alike. Brio's services span complex financial analysis, accounting for mergers and acquisitions, valuation of financial instruments, and the development of robust financial reporting frameworks. In addition to ensuring compliance and managing financial reporting and taxation, the firm provides strategic financial management solutions, including budgeting, modeling, capital procurement and accounting system design. Brio is known for helping emerging growth companies navigate financial complexity with clarity and confidence.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The company's pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumours for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bispecific antibody-drug conjugates (ADCs), currently in discovery. The company also advances two pre-IND candidates: (i) Leumuna, an oral immune checkpoint modulator aimed at achieving durable remission in posttransplant leukemia relapse; and (ii) Gemceda, a first-in-class oral gemcitabine pro drug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

We seek Safe Harbor.